Plasma myeloperoxidase level and peripheral arterial disease

European Journal of Clinical Investigation

Volumn 42, Issue 5, 2012, Pages 463-469

  Haslacher, Helmuth ^a   Perkmann, Thomas ^a   Gruenewald, Julia ^a   Exner, Markus ^a   Endler, Georg ^b   Scheichenberger, Vanessa ^a   Wagner, Oswald ^a   Schillinger, Martin ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b WILHELMINEN HOSPITAL   (Austria)

Author keywords

Gender specific; MACE; MPO 463G>A; PAD; Plasma myeloperoxidase; Smoking

Indexed keywords

MYELOPEROXIDASE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; ENZYME BLOOD LEVEL; FEMALE; GENOTYPE; HAZARD RATIO; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; VASCULAR DISEASE;

AGED; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; PEROXIDASE; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; RISK FACTORS;

EID: 84859700991     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2011.02601.x     Document Type: Article

References (35)

1. van der Veen BS, de Winther MP, Heeringa P. Myeloperoxidase: molecular mechanisms of action and their relevance to human health and disease. Antioxid Redox Signal 2009;11:2899-937.
2. Klebanoff SJ. Myeloperoxidase: friend and foe. J Leukoc Biol 2005;77:598-625.
3. Dahlgren C, Karlsson A. Respiratory burst in human neutrophils. J Immunol Methods 1999;232:3-14.
4. Johnson RJ, Couser WG, Chi EY, Adler S, Klebanoff SJ. New mechanism for glomerular injury. Myeloperoxidase-hydrogen peroxide-halide system. J Clin Invest 1987;79:1379-87.
5. Arnhold J, Flemmig J. Human myeloperoxidase in innate and acquired immunity. Arch Biochem Biophys 2010;500:92-106.
6. Nicholls SJ, Hazen SL. Myeloperoxidase, modified lipoproteins, and atherogenesis. J Lipid Res 2009;50(Suppl):S346-51.
7. Shao B, Oda MN, Oram JF, Heinecke JW. Myeloperoxidase: an oxidative pathway for generating dysfunctional high-density lipoprotein. Chem Res Toxicol 2010;23:447-54.
8. Heinecke JW. The role of myeloperoxidase in HDL oxidation and atherogenesis. Curr Atheroscler Rep 2007;9:249-51.
9. Shao B, Oda MN, Oram JF, Heinecke JW. Myeloperoxidase: an inflammatory enzyme for generating dysfunctional high density lipoprotein. Curr Opin Cardiol 2006;21:322-8.
10. Sinning C, Schnabel R, Peacock WF, Blankenberg S. Up-and-coming markers: myeloperoxidase, a novel biomarker test for heart failure and acute coronary syndrome application? Congest Heart Fail 2008;14:46-8.
11. Loria V, Dato I, Graziani F, Biasucci LM. Myeloperoxidase: a new biomarker of inflammation in ischemic heart disease and acute coronary syndromes. Mediators Inflamm 2008;2008:135625.
12. Schindhelm RK, van der Zwan LP, Teerlink T, Scheffer PG. Myeloperoxidase: a useful biomarker for cardiovascular disease risk stratification? Clin Chem 2009;55:1462-70.
13. Piedrafita FJ, Molander RB, Vansant G, Orlova EA, Pfahl M, Reynolds WF. An Alu element in the myeloperoxidase promoter contains a composite SP1-thyroid hormone-retinoic acid response element. J Biol Chem 1996;271:14412-20.
14. Nagra RM, Becher B, Tourtellotte WW, Antel JP, Gold D, Paladino T et al. Immunohistochemical and genetic evidence of myeloperoxidase involvement in multiple sclerosis. J Neuroimmunol 1997;78:97-107.
15. Reynolds WF, Chang E, Douer D, Ball ED, Kanda V. An allelic association implicates myeloperoxidase in the etiology of acute promyelocytic leukemia. Blood 1997;90:2730-7.
16. Taioli E, Benhamou S, Bouchardy C, Cascorbi I, Cajas-Salazar N, Dally H et al. Myeloperoxidase G-463A polymorphism and lung cancer: a HuGE genetic susceptibility to environmental carcinogens pooled analysis. Genet Med 2007;9:67-73.
17. London SJ, Lehman TA, Taylor JA. Myeloperoxidase genetic polymorphism and lung cancer risk. Cancer Res 1997;57:5001-3.
18. Cascorbi I, Henning S, Brockmoller J, Gephart J, Meisel C, Muller JM et al. Substantially reduced risk of cancer of the aerodigestive tract in subjects with variant-463A of the myeloperoxidase gene. Cancer Res 2000;60:644-9.
19. Le Marchand L, Seifried A, Lum A, Wilkens LR. Association of the myeloperoxidase -463G-->a polymorphism with lung cancer risk. Cancer Epidemiol Biomarkers Prev 2000;9:181-4.
20. Zappia M, Manna I, Serra P, Cittadella R, Andreoli V, La Russa A et al. Increased risk for Alzheimer disease with the interaction of MPO and A2M polymorphisms. Arch Neurol 2004;61:341-4.
21. Reynolds WF, Rhees J, Maciejewski D, Paladino T, Sieburg H, Maki RA et al. Myeloperoxidase polymorphism is associated with gender-specific risk for Alzheimer's disease. Exp Neurol 1999;155:31-41.
22. Reynolds WF, Hiltunen M, Pirskanen M, Mannermaa A, Helisalmi S, Lehtovirta M et al. MPO and APOE{epsilon}4 polymorphisms interact to increase risk for AD in Finnish males. Neurology 2000;55:1284-90.
23. Makela R, Dastidar P, Jokela H, Saarela M, Punnonen R, Lehtimaki T. Effect of long-term hormone replacement therapy on atherosclerosis progression in postmenopausal women relates to myeloperoxidase promoter polymorphism. J Clin Endocrinol Metab 2003;88:3823-8.
24. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg 2000;31:S1-296.
25. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined - a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000;36: 959-69.
26. Schillinger M, Exner M, Amighi J, Mlekusch W, Sabeti S, Rumpold H et al. Joint effects of C-reactive protein and glycated hemoglobin in predicting future cardiovascular events of patients with advanced atherosclerosis. Circulation 2003;108:2323-8.
27. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med 2007;4:e296.
28. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010;40: 35-53.
29. Shih J, Datwyler SA, Hsu SC, Matias MS, Pacenti DP, Lueders C et al. Effect of collection tube type and preanalytical handling on myeloperoxidase concentrations. Clin Chem 2008;54:1076-9.
30. Wenten M, Gauderman WJ, Berhane K, Lin P-C, Peters J, Gilliland FD. Functional variants in the catalase and myeloperoxidase genes, ambient air pollution, and respiratory-related school absences: an example of epistasis in gene-environment interactions. Am J Epidemiol 2009;170:1494-501.
31. Grundy SM, Pasternak R, Greenland P, Smith S Jr, Fuster V. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations : a statement for Healthcare Professionals From the American Heart Association and the American College of Cardiology. Circulation 1999;100:1481-92.
32. Ali Z, Sarcia P, Mosley TH Jr, Kondragunta V, Kullo IJ. Association of serum myeloperoxidase with the ankle-brachial index and peripheral arterial disease. Vasc Med 2009;14:215-20.
33. Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003;349:1595-604.
34. Baldus S, Heeschen C, Meinertz T, Zeiher AM, Eiserich JP, Munzel T et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003;108:1440-5.
35. Brevetti G, Schiano V, Laurenzano E, Giugliano G, Petretta M, Scopacasa F et al. Myeloperoxidase, but not C-reactive protein, predicts cardiovascular risk in peripheral arterial disease. Eur Heart J 2008;29:224-30.